Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
TRANSFUSION OF DONOR BUFFY COAT CELLS IN THE TREATMENT OF PERSISTENT OR RECURRENT MALIGNANCY AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION
Autore:
COLLINS RH; PINEIRO LA; NEMUNAITIS JJ; JAIN VK; WAXMAN D; MILLER WV; FAY JW;
Indirizzi:
BAYLOR UNIV,MED CTR,BONE MARROW TRANSPLANT PROGRAM,SAMMONS TOWER,SUITE 605,3409 WORTH ST DALLAS TX 75246 TEXAS ONCOL PA,CLIN RES DALLAS TX 00000 BLOODCARE,BLOOD SERV DALLAS TX 00000
Titolo Testata:
Transfusion
fascicolo: 11, volume: 35, anno: 1995,
pagine: 891 - 898
SICI:
0041-1132(1995)35:11<891:TODBCC>2.0.ZU;2-1
Fonte:
ISI
Lingua:
ENG
Soggetto:
GRAFT-VERSUS-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; HOST-DISEASE; LEUKOCYTE INFUSIONS; INTERFERON-ALPHA; T-CELLS; IMMUNOSUPPRESSION; DISCONTINUATION; IMMUNOTHERAPY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
41
Recensione:
Indirizzi per estratti:
Citazione:
R.H. Collins et al., "TRANSFUSION OF DONOR BUFFY COAT CELLS IN THE TREATMENT OF PERSISTENT OR RECURRENT MALIGNANCY AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION", Transfusion, 35(11), 1995, pp. 891-898

Abstract

Background: Patients who experience relapse after allogeneic bone marrow transplantation have a poor prognosis. However, preclinical and clinical data have strongly suggested the existence of an immune-mediated anti-tumor effect of allogeneic bone marrow transplantation. This effect, termed graft-versus-leukemia, may be harnessed purposefully in patients with posttransplant relapses by the administration of immune cells obtained by leukapheresis of the original bone marrow donor. Study Design and Methods: Thirteen patients with persistent or recurrent hematologic malignancy after HLA-matched sibling-donor allogeneic bone marrow transplantation were treated with transfusion of buffy coat cells collected from the original bone marrow donors. Mononuclear cell doses ranged from 1.18 to 4.28 x 10(8) per kg. Alpha-interferon (1.5-3 x10(6) U/m(2) 3-5x/week) was given to seven patients. Patients were observed for the development of graft-versus-host disease and disease response. Results: Three of five patients with chronic myelogenous leukemia had complete remissions. One of five patients with active acute leukemia attained complete remission. A sixth acute leukemia patient treated with buffy coat transfusion after the induction of remission withchemotherapy relapsed 12 months later. One patient with myeloma had acomplete but transient response. A patient with Hodgkin's disease didnot respond. Four patients remain in remission 4, 16, 17, and 29 months after attaining complete remission. Graft-versus-host disease occurred in eight patients, including all of those with a complete response. One patient developed transient pancytopenia. Conclusion: The transfusion of donor buffy coat cells has significant anti-tumor activity inpatients with relapsed hematologic malignancy after allogeneic bone marrow transplantation. This effect is strongly associated with graft-versus-host disease.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 13/07/20 alle ore 10:16:22